Interactive Agenda Click on the ABSTRACT button to see details for each item
TUESDAY SEPTEMBER 14 |
8:30a - 6:00p |
REGISTRATION
|
| 1:30p - 5:00p |
This session features short presentations from companies involved in the development of peptide therapeutics or peptide related technologies. A full list of companies will be listed soon. |
5:30p - 6:30p |
OPENING NIGHT RECEPTION |
|
WEDNESDAY SEPTEMBER 15 |
7:30a - 8:30a |
BREAKFAST |
| 8:30a – 11:25a |
Shk Peptides For The Treatment Of Autoimmune Disease  Shawn Iadonato, Chief Scientific Officer Kineta Bio
Oral Delivery of Peptides using GIPET® Technology  Tom Leonard,Vice President & Chief Scientific Officer Merrion Pharmaceuticals
Development Of Xen2174, A Novel Intrathecal Analgesic (Abstract not yet available) Peter Schmidt, Product Development Manager Xenome Ltd
Guanylate Cyclase-C Agonists as a New Class of Drug Candidates for GI disorders and Inflammatory Bowel Disease  Kunwar Shailubhai, Chief Scientific Officer Synergy Pharmaceuticals
|
11:25a – 12:25p |
|
12:25p – 1:25p |
LUNCH |
1:25p – 4:30p |
The Role Of Peptide Properties During Microencapsulation And Extended-Release From Bioresorbable Polymers
 Tom Tice, Vice-President Research Surmodics Inc
Are today's medicinal chemists better prepared to design therapeutic peptides that exhibit good oral bioavailability?
 Ronald T. Borchardt
, Solon E. Summerfield Distinguished Professor The University Of Kansas
TPE, A Unique Formulation Based Technology Enabling Oral Delivery Of Macromolecules
 Roni Mamluk
, Chief Operating Officer Chiasma
PEGylation: a successful strategy in parenteral drug delivery
 Francesco M. Veronese
, Professor, Applied Pharmaceutical Chemistry Padua University
|
6:00p – 7:00p |
MEIENHOFER AWARD PRESENTATION |
7:00p – 9:00p |
GALA DINNER AT THE RED LION INN |
|
THURSDAY SEPTEMBER 16 |
7:00a – 8:00a |
BREAKFAST |
8:00a – 12:20p |
Development Of A Nonapeptide (Syn1002) For The Treatment Of Autoimmune Diseases And Neuropathic Pain  Jamal Temsamani, Vice-President R&D CLL Pharma
An HDL mimetic peptide that stimulates cellular cholesterol efflux(Working Title)(Abstract not yet available) Jan Johannson, Artery Therapeutics
Pepducins: Novel Lipopeptide Allosteric Modulators Of Gpcr Signaling

Steve Hunt, Chief Scientific Officer Anchor Therapeutics
Targeted Delivery of Bioactive Cell Penetrating Peptides: Implications for Anti-cancer Therapy
 John Howl, Professor of Molecular Pharmacology University of Wolverhampton
Ensemblins: A New Class Of Therapeutic Macrocycles
 Nicholas Terrett, Chief Scientific Officer Ensemble Discovery Corp.
Cyclotides, a novel natural peptide scaffold for drug discovery
 Julio Camarero, Associate Professor fo Pharmacology Univ. of Southern California
|
12:20p – 1:20p |
LUNCH |
1:20p – 3:20p |
Peptides On Synthetic Scaffolds For Mimicry Of Proteins Towards Synthetic Vaccines And Beyond
 Rob M.J. Liskamp
, Professor Utrecht University
Analytical Challenges On Pegylated Peptide API
 Ping Zhuang
, Research Fellow Merck and Co. |
3:20p – 5:30p |
|
6:00p – 8:00p |
NETWORKING RECEPTION |
|